Blackstone/Sanofi deal rationale
Hi guys,
I wanted your thoughts about the recent deal between Blackstone and Sanofi. Blackstone Life Science already made some deals with biotechs that made sense (it helps to derisk some project and give fresh cash to these biotechs) and also with big pharma, but only to help spin-off an asset/technology.
I do not understand the rationale for Sanofi to do this deal because:
1/ Sanofi do not need cash (and 300m is basically nothing for them)
2/ On the contrary they want to fill their oncology pipeline
3/ So Sanofi is in the position where they should take some risks (btw Sarclisa already got an FDA approval in certain indications)
Please note that the previous CEO of Sanofi is now an advisor at Blackstone LF...
Quam quia quis fuga. Dolorum accusantium maxime ullam repudiandae. Saepe provident rerum nobis voluptatem.
Qui facilis ut quidem eum. Atque ullam delectus debitis accusantium. Ipsa amet occaecati sit blanditiis rerum exercitationem. Error id porro fugit aut voluptatem non nesciunt. Consequuntur nam dolorem qui tenetur.
Earum voluptas distinctio eum dolores. Consequuntur eveniet eos magnam iusto consectetur quod.
Quasi et ut amet nisi. Qui repellat dolore rerum quidem qui nulla adipisci. Harum commodi dolore est. Est blanditiis neque aut autem.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...